Financials data is unavailable for this security.
View more
Year on year Cyfuse Biomedical KK 's revenues fell -83.68% from 374.48m to 61.11m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 473.96m to a larger loss of 589.21m.
Gross margin | 58.30% |
---|---|
Net profit margin | -1,103.48% |
Operating margin | -1,285.68% |
Return on assets | -16.32% |
---|---|
Return on equity | -21.19% |
Return on investment | -19.11% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Cyfuse Biomedical KK fell by 563.53m. Cash Flow from Financing totalled 18.24m or 29.84% of revenues. In addition the company used 562.30m for operations while cash used for investing totalled 19.47m.
Cash flow per share | -80.00 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 360.49 |
---|---|
Tangible book value per share | 359.90 |
More ▼
Balance sheet in JPYView more
Current ratio | 6.11 |
---|---|
Quick ratio | 6.02 |
Total debt/total equity | 0.2743 |
---|---|
Total debt/total capital | 0.2153 |
More ▼